Endothelin-1 (ET-1) produced by various cancers is known to be responsible for inducing pain. While ET-1 binding to ETAR on peripheral nerves clearly mediates nociception, effects from binding to ETBR are less clear. The present study assessed the effects of ETBR activation and the role of endogenous opioid analgesia in carcinoma pain using an orthotopic cancer pain mouse model. mRNA expression analysis showed that ET-1 was nearly doubled while ETBR was significantly down-regulated in a human oral SCC cell line compared to normal oral keratinocytes (NOK). Squamous cell carcinoma (SCC) cell culture treated with an ETBR agonist (10 À4 M, 10 À5 M, and 10 À6 M BQ-3020) significantly increased the production of bendorphin without any effects on leu-enkephalin or dynorphin. Cancer inoculated in the hind paw of athymic mice with SCC induced significant pain, as indicated by reduction of paw withdrawal thresholds in response to mechanical stimulation, compared to sham-injected and NOK-injected groups. Intratumor administration of 3 mg/kg BQ-3020 attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection, while intratumor ETBR antagonist BQ-788 treatment (100 and 300 lg/kg and 3 mg/kg) had no effects. Local naloxone methiodide (500 lg/kg) or selective l-opioid receptor antagonist (CTOP, 500 lg/kg) injection reversed ETBR agonist-induced antinociception in cancer animals. We propose that these results demonstrate that peripheral ETBR agonism attenuates carcinoma pain by modulating b-endorphins released from the SCC to act on peripheral opioid receptors found in the cancer microenvironment. Ó
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Introduction
Pain is a frequent and disabling consequence of many types of cancers in humans. It is a primary determinant of a poor quality of life, especially in head and neck cancer patients [11] . Eighty-five percent of cancer patients experience severe pain in their final days of life [60] and up to ninety percent of those in terminal stages must cope with opiate-resistant pain related to tumor progression [39, 40, 52, 55] . The etiology of cancer pain is unknown, but may involve mediator-dependent signaling by cancer cells to primary afferent sensory neurons in the cancer microenvironment. One candidate mediator is endothelin-1 (ET-1) [48, 58, 49] , a vasoactive 21-amino acid peptide first isolated from porcine aortic endothelial cells [66] . ET-1 is a member of the endothelin family, which includes ET-2, ET-3, and the sarafotoxins [31, 35] , and is synthesized from its precursor, pre-pro ET-1, through a proteolytic cleavage by endothelin-converting enzyme (ECE) [27] . The physiological actions of endothelin are mediated by two G-protein-coupled receptors (GPCRs), endothelin A (ETAR) and endothelin B (ETBR), which have been successfully cloned in mammals [3, 56] .
ET-1 is synthesized by neurons and glial cells in the central and peripheral nervous systems [25, 36] and may serve as an algogen to induce nociception. Studies in animals have demonstrated that injection of ET-1 evokes tactile allodynia [6] , hyperalgesia from thermal [18] and mechanical [21] stimulations, and overt inflammatory nociception [21, 19, 51] . ET-1 also causes pain in humans through activation and sensitization of C nociceptors [28, 42] . In addition to mediating nociception in noncancerous conditions, ET-1 also plays a role in cancer pain. ET-1 is highly expressed in different cancers, including bone [63, 48] [9, 16, 18, 24, 48, 49, 58, 69] , specifically by antagonizing ETARs present on primary afferent nociceptors [17, 26] .
Whereas the role of ETAR in ET-1-induced pain is well characterized, the importance of ETBR for this pain is less clear. In rats, ETBR is 
